People · Operator
Named in public records as an officer, director or promoter · active 2010–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cara Therapeutics, Inc. | — | Biotechnology | Series A | $4.9M | $3.6M | 2010 |
Dean Slagel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dean Slagel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Hurwitz | 1 | 9 |
| Stephen Reeders | 1 | 9 |
| Michael E Lewis | 1 | 4 |
| Martin Vogelbaum | 1 | 3 |
| Jeffrey L. Ives | 1 | 3 |
| Jeffrey M. Jonas | 1 | 2 |
| Harrison Bains | 1 | 2 |
| Joseph W. Stauffer | 1 | 1 |
| Frederique Menzaghi | 1 | 1 |
| Josef Schoell | 1 | 1 |
| Christopher M. Moller | 1 | 1 |
| Derek Chalmers | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.